Get started
Author

Duleek Nimantha Bandara Ranatunga

Observed names: Duleek N. Ranatunga, Duleek Ranatunga
Observed institution: Ourotech Limited (United Kingdom)
ORCID: 0000-0002-7041-2970
Observed ORCID: 0000-0002-7041-2970
OpenAlex ID: A5113232182
Developing a functional precision medicine assay to predict pathological complete response in patients with triple-negative breast cancer: Interim results from the PEAR-TNBC Trial
2024 · Peter Hall, Matthew Williams, et al. · medRxiv · 2
Clinical validation of image-based AI predictive biomarkers for precision neoadjuvant triple-negative breast cancer treatment (PEAR-TNBC).
2024 · Matthew Williams, Eleonora Peerani, et al. · Journal of Clinical Oncology · 1
Exploring Personalised Glioblastoma Therapies Through Functional Precision Medicine: Early Data From Pear-glio
2025 · Matt Williams, Eleonora Peerani, et al. · Neuro-Oncology
PDF
Abstract P3-01-18: Clinical validation of image-based AI predictive biomarkers for precision neoadjuvant triple-negative breast cancer treatment (PEAR-TNBC): Interim results from Cohort A
2025 · Peter Hall, Matthew Williams, et al. · Clinical Cancer Research
Transforming kidney cancer treatment through AI-enabled functional precision medicine: The PEAR-TREE2 trial.
2025 · Matthew Williams, Ekaterini Boleti, et al. · Journal of Clinical Oncology
PEAR-GLIO: Clinical evaluation of an AI-driven functional precision medicine platform for therapeutic efficacy in gliomas.
2025 · Matthew Williams, Eleonora Peerani, et al. · Journal of Clinical Oncology
PDF
Abstract 3011: Novel CDK12 inhibitors with preclinical anti-tumor activity and best-in-class profile on HER2 low breast cancer patient samples
2025 · Chandan Seth Nanda, Maria New, et al. · Cancer Research
Abstract 3917: A functional precision medicine assay for immunotherapy and combination therapy testing in liver and pancreatic cancers (PEAR-PAL)
2025 · Eleonora Peerani, Farah Sangkolah, et al. · Cancer Research
Abstract 4724: Evaluating immunotherapy and combination therapy efficacy in kidney cancer using a multicellular 3D immune-microtumor model
2025 · Eleonora Peerani, Keqian Nan, et al. · Cancer Research
Abstract B021: Optimizing combination immunotherapy regimens in kidney cancer using ex-vivo multicellular 3D immune-microtumors and multiplex immunoassays
2025 · Roseanna Hare, Eleonora Peerani, et al. · Cancer Immunology Research
18 Multivariate analysis of ex vivo kidney 3D immune-microtumors for functional precision medicine: development, translation and application of a novel platform to predict treatment response
2024 · Jay Kearney, Keqian Nan, et al. · Journal for ImmunoTherapy of Cancer
Abstract 6767: Multivariate analysis of ex vivo kidney 3D immune-microtumors for functional precision medicine
2024 · Eleonora Peerani, Keqian Nan, et al. · Cancer Research
Development of a kidney cancer ex vivo tumor model and image-based artificial intelligence tool for precision immunotherapy and combination therapy testing.
2023 · Eleonora Peerani, Jay Kearney, et al. · Journal of Clinical Oncology
PDF
Works count: 13
Citation count: 3
H-index: 1
I10-index:
Year
Topic
Type